Cryofocus Medtech (Shanghai) Valuation
Is 6922 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Book gegen Gleichaltrige
Price-To-Book gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 6922 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 6922 (HK$12.48) wird unter unserer Schätzung des Fair Value (HK$58.36) gehandelt.
Deutlich unter dem Marktwert: 6922 wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6922?
Other financial metrics that can be useful for relative valuation.
| What is 6922's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥2.08b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 48.7x |
| Enterprise Value/EBITDA | -17.3x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 6922's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
2160 MicroPort CardioFlow Medtech | 0.9x | 112.6% | HK$2.2b |
6669 Acotec Scientific Holdings | 1.7x | 48.0% | HK$2.4b |
2235 MicroTech Medical (Hangzhou) | 0.8x | 91.2% | HK$1.7b |
1358 PW Medtech Group | 0.3x | n/a | HK$1.5b |
6922 Cryofocus Medtech (Shanghai) | 12.9x | 68.5% | HK$2.2b |
Price-To-Book gegen Gleichaltrige: 6922 ist auf der Grundlage des Price-To-Book Verhältnisses (13.4x) im Vergleich zum Durchschnitt der Vergleichsgruppe (1.2x) teuer.
Price to Earnings Ratio vs Industry
How does 6922's PE Ratio compare vs other companies in the HK Medical Equipment Industry?
Price-To-Book gegen Industrie: 6922 ist teuer, wenn man sein Price-To-Book Verhältnis (13.4x) mit dem Hong Kong Medical Equipment Branchendurchschnitt (1.3x) vergleicht.
Price to Book Ratio vs Fair Ratio
What is 6922's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 12.9x |
| Fair PB Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Book Fair Ratio von 6922 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$9.40 | HK$28.02 +198.1% | 0.1% | HK$28.06 | HK$27.98 | n/a | 2 |
| Mar ’25 | HK$10.74 | HK$28.02 +160.9% | 0.1% | HK$28.06 | HK$27.98 | n/a | 2 |
| Feb ’25 | HK$10.78 | HK$28.02 +159.9% | 0.1% | HK$28.06 | HK$27.98 | n/a | 2 |
| Jan ’25 | HK$18.82 | HK$28.13 +49.5% | 0.5% | HK$28.26 | HK$28.00 | n/a | 2 |
Analysten-Prognose: Das Kursziel liegt mehr als 20% über dem aktuellen Aktienkurs, aber es gibt nicht genügend Analysten, die die Aktie beobachten, um eine statistische Sicherheit für eine Übereinstimmung zu ermitteln.